WHV has invited three highly experienced experts in HIV vaccine clinical studies to form a Safety Monitoring Board (SMB) for the WHV 138 trial. The SMB will be responsible for the continued safety of the study participants and the validity as well as scientific merit of the trial. The following three HIV vaccine experts will share their expertise and professional opinion during the conduct of this trial:
Dr. Marnie Elizaga is the chair of the SMB. She is a board-certified infectious disease physician with 20 years’ experience overseeing clinical trials of investigational HIV vaccines with the NIH-funded HIV Vaccine Trials Network. She is currently an independent consultant.
Dr. Michael Keefer, the co-chair of the SMB, is a board-certified infectious disease specialist with 30 years of experience in the field of preventative HIV vaccines. He currently is the Interim Chief of Infectious Diseases at the University of Rochester and the Principal Investigator of their HIV/AIDS Clinical Trials Unit, which works with the HIV Vaccine Trials Network (HVTN) and the AIDS Clinical Trials Group (ACTG).
Dr. Yunda Huang is a faculty statistician and Co-Principal Investigator of the HVTN Statistical and Data Management Center within the Fred Hutchinson Cancer Research Center. Dr. Huang has 20 years of experience in providing statistical leadership in the design and analysis of early- and late-phase HIV clinical trials. Her expertise as a biostatistician is highly valuable to the WHV138 trial.
